A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Trial Details

NCT ID

NCT07791745

Phase

PHASE2 / PHASE3

Sponsor

Taizhou Mabtech Pharmaceutical Co.,Ltd

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

• Enlituo® + Anyouping® + PBC
• Placebo-Enlituo + Anyouping® + PBC

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• Voluntarily sign the written informed consent form and be willing to comply with all requirements specified in the study protocol;
• Aged ≥ 18 years;
• Histologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (including oral cavity, oropharynx, …
• Have not received any systemic therapy for recurrent or metastatic disease. Note: If disease progression occurs during neoadjuvant/adjuvant therapy…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.